New insider activity at Moderna ( (MRNA) ) has taken place on December 15, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director Noubar Afeyan has recently sold 23,853 shares of Moderna stock, generating a total of $703,186 from the transaction.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
Moderna’s overall stock score is primarily impacted by its financial performance challenges, including declining revenues and profitability. While technical analysis shows positive momentum, valuation concerns due to negative earnings weigh heavily. The earnings call and corporate events provide some optimism with strategic cost reductions and financial planning, but significant risks remain.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
YTD Price Performance: -29.86%
Average Trading Volume: 10,873,048
Technical Sentiment Signal: Sell
Current Market Cap: $11.51B